Please assess the completion status of the following clinical trial:

Trial Title: XP13512 vs. Placebo in Patients With Restless Legs Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary RLS, based on the International RLS Study Diagnostic Criteria.~Exclusion Criteria:~* A sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of RLS;~* Neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's Disease, Multiple Sclerosis, dyskinesias, and dystonias);~* Abnormal laboratory results, electrocardiogram (ECG) or physical findings;~* Pregnant or lactating women;~* Women of childbearing potential who are not practicing an acceptable method of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XP13512 600MG (Type: EXPERIMENTAL): XP13512 600MG ONCE DAILY
- XP13512 1200MG (Type: EXPERIMENTAL): XP13512 1200MG ONCE DAILY
- Placebo (Type: PLACEBO_COMPARATOR): PLACEBO ONCE DAILY

Based on this trial design, predict the completion outcome and termination type (if applicable).